On November 17, the company answered on the interactive platform that currently the phase III clinical trial of the company's ACC017 tablets is progressing steadily according to the established plan and plan. The trial is a multicenter, randomized, double-blind, double simulation study, using dotilavr sodium tablets as a positive control to evaluate the efficacy and safety of ACC017 tablets in first-time HIV-infected adult patients. Following up on relevant data and important developments, the company will promptly fulfill its disclosure obligations in accordance with the clinical trial plan and information disclosure rules to ensure scientific test results and complete data compliance. Innovative drug research and development investment is large, the cycle is long, and the risk is high. Please pay attention to the investment risks.

Zhitongcaijing · 1d ago
On November 17, the company answered on the interactive platform that currently the phase III clinical trial of the company's ACC017 tablets is progressing steadily according to the established plan and plan. The trial is a multicenter, randomized, double-blind, double simulation study, using dotilavr sodium tablets as a positive control to evaluate the efficacy and safety of ACC017 tablets in first-time HIV-infected adult patients. Following up on relevant data and important developments, the company will promptly fulfill its disclosure obligations in accordance with the clinical trial plan and information disclosure rules to ensure scientific test results and complete data compliance. Innovative drug research and development investment is large, the cycle is long, and the risk is high. Please pay attention to the investment risks.